Abstract
<div>Abstract<p>New targeted approaches to ovarian clear cell carcinomas (OCCC) are needed, given the limited treatment options in this disease and the poor response to standard chemotherapy. Using a series of high-throughput cell-based drug screens in OCCC tumor cell models, we have identified a synthetic lethal (SL) interaction between the kinase inhibitor dasatinib and a key driver in OCCC, <i>ARID1A</i> mutation. Imposing ARID1A deficiency upon a variety of human or mouse cells induced dasatinib sensitivity, both <i>in vitro</i> and <i>in vivo</i>, suggesting that this is a robust synthetic lethal interaction. The sensitivity of <i>ARID1A</i>-deficient cells to dasatinib was associated with G<sub>1</sub>–S cell-cycle arrest and was dependent upon both p21 and Rb. Using focused siRNA screens and kinase profiling, we showed that <i>ARID1A</i>-mutant OCCC tumor cells are addicted to the dasatinib target YES1. This suggests that dasatinib merits investigation for the treatment of patients with <i>ARID1A</i>-mutant OCCC. <i>Mol Cancer Ther; 15(7); 1472–84. ©2016 AACR</i>.</p></div>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
